Governance WuXi Biologics (Cayman) Inc. OTC Markets

WXXWY

US98260N1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:59 2026-06-17 pm EDT			5-day change	1st Jan Change
7.450 ^USD	-2.10%		-2.23%	-6.88%

Jun. 17	CANbridge Pharmaceuticals Enters Service Agreements With WuXi Biologics, Baheal Medical	MT
Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI

Executive Committee: WuXi Biologics (Cayman) Inc.

Manager

Positions heldSince

Zhi Sheng Chen

54 year

Chief Executive Officer

2015-12-31

Lihua Yu

Chief Operating Officer

Lina Fan

Investor Relations Contact

Xuejun Gu

55 year

Chief Tech/Sci/R&D Officer

2024-03-30

He Wang

Compliance Officer	-
General Counsel	-

Li Xiong

Human Resources Officer

Ying Man Sham

Corporate Secretary

Ji Jie Gu

59 year

Chief Tech/Sci/R&D Officer

Ming Tu

56 year

Director of Finance/CFO

2021-08-22

Yue Huang

Corporate Secretary

2018-11-19

Composition of the Board of Directors: WuXi Biologics (Cayman) Inc.

Director

CommitteesSince

Ge Li

59 year

Finance Committee	2003-12-31
Compensation Committee	2003-12-31
Nominating Committee
Nominating Committee Chair	2014-01-31

William Keller

77 year

Audit Committee	2018-08-25
Governance Committee	2017-05-16
Nominating Committee	2018-08-25
Compensation Committee Chair	2018-08-25

Kenneth Hitchner

65 year

Audit Committee	2024-11-20
Compensation Committee	2024-11-20
Governance Committee	2020-06-08
Nominating Committee	2025-06-26

Jackson Tai

75 year

Compensation Committee	2023-08-15
Nominating Committee	2023-05-05
Audit Committee Chair	2024-10-16
Governance Committee	2024-10-16

Zhi Sheng Chen

54 year

Governance Committee Chair	2014-01-31
Nominating Committee Chair	2020-11-30

Jue Chen

56 year

Governance Committee	2023-08-15
Nominating Committee	2025-06-05

Jingwen Miao

Director/Board Member

2024-11-19

Xuejun Gu

55 year

Director/Board Member

2025-06-05

Yan Ling Cao

42 year

Director/Board Member

2016-04-30

Former Officers and Directors: WuXi Biologics (Cayman) Inc.

Insider

Positions held

SinceUntil

Wei Chang Zhou

Director/Board Member	2016-04-30	2025-06-05
Chief Tech/Sci/R&D Officer	2016-10-31	2024-03-30

Yi Bing Wu

Director/Board Member

2016-04-30

2024-11-19

Ning Zhao

Director/Board Member

2021-06-15

2023-05-15

Teh Ming Kwauk

Director/Board Member	2017-05-16	2022-11-23
Independent Dir/Board Member	2017-05-16	2022-11-23

Shao Hua Lu-Wong

Director of Finance/CFO

2016-01-09

2021-10-31

Jian Jun Luo

Corporate Officer/Principal

2021-07-31

Edward Hu

Director/Board Member

2014-01-31

2021-06-15

Cong Ding

General Counsel

2020-07-31

Wo Fong

Director/Board Member	2017-04-30	2020-06-08
Independent Dir/Board Member	2017-04-30	2020-06-08

Tong Yong

Chief Operating Officer	2015-05-31	-
Corporate Secretary	2016-04-30	2018-11-19

Min MIn Qin

Corporate Officer/Principal

2017-07-31

2018-02-28

Chiang Syin

Corporate Officer/Principal

2018-01-13

Eileen Wang

Director/Board Member	2017-04-30	2022-12-31
Investor Relations Contact	2017-04-30	-

Pik Yuk Cheng

Corporate Secretary

2017-03-31

Zhao Hui Zhang

Director/Board Member

Zhi Ling Ji

General Counsel

Xiao Zhong Liu

Director/Board Member

Li Li

Director/Board Member

Harry He

Director/Board Member

Xiang Li Liu

Chairman

Keqiang Shen

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	15
Female	5

Of which Executive Committee

Male	7
Female	3

Of which Directors

Male	8
Female	1

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Employees

13,252

Sector

Biotechnology & Medical Research

More about the company